- Home
- TNON vs PCSA Comparison
TNON vs PCSA Comparison
Compare TNON & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- PCSA
- Stock Information
- Founded
- TNON 2012
- PCSA 2011
- Country
- TNON United States
- PCSA United States
- Employees
- TNON N/A
- PCSA N/A
- Industry
- TNON Medical Specialities
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- PCSA Health Care
- Exchange
- TNON Nasdaq
- PCSA Nasdaq
- Market Cap
- TNON 11.5M
- PCSA 12.0M
- IPO Year
- TNON 2022
- PCSA N/A
- Fundamental
- Price
- TNON $1.18
- PCSA $0.48
- Analyst Decision
- TNON Strong Buy
- PCSA Strong Buy
- Analyst Count
- TNON 2
- PCSA 1
- Target Price
- TNON $5.50
- PCSA $1.00
- AVG Volume (30 Days)
- TNON 158.8K
- PCSA 21.2M
- Earning Date
- TNON 11-12-2025
- PCSA 10-29-2025
- Dividend Yield
- TNON N/A
- PCSA N/A
- EPS Growth
- TNON N/A
- PCSA N/A
- EPS
- TNON N/A
- PCSA N/A
- Revenue
- TNON $2,947,000.00
- PCSA N/A
- Revenue This Year
- TNON $43.52
- PCSA N/A
- Revenue Next Year
- TNON $82.14
- PCSA N/A
- P/E Ratio
- TNON N/A
- PCSA N/A
- Revenue Growth
- TNON N/A
- PCSA N/A
- 52 Week Low
- TNON $0.85
- PCSA $0.15
- 52 Week High
- TNON $5.85
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- TNON 46.33
- PCSA 86.63
- Support Level
- TNON $1.15
- PCSA $0.19
- Resistance Level
- TNON $1.25
- PCSA $0.21
- Average True Range (ATR)
- TNON 0.04
- PCSA 0.04
- MACD
- TNON 0.00
- PCSA 0.03
- Stochastic Oscillator
- TNON 30.43
- PCSA 78.50
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).